Förfarande för framställning av aktiverbara fibrinolytiska och antikombotiska plasminogenanaloga

摘要

PCT No. PCT/GB90/01911 Sec. 371 Date Jun. 3, 1992 Sec. 102(e) Date Jun. 3, 1992 PCT Filed Dec. 7, 1990 PCT Pub. No. WO91/09125 PCT Pub. Date Jun. 27, 1991.Relatively inactive fusion proteins are activatable by enzymes of the clotting cascade to have fibrinolytic and/or clot formation inhibition activity. For example, a fusion protein comprising two hirudin or streptokinase molecules, linked by a cleavable linkage sequence, may be cleaved to yield anti-thrombotic hirudin or fibrinolytic streptokinase by thrombin or Factor Xa. Fibrinolytic or clot formation inhibition activity is therefore directed to the site of clot formation. Cleavable streptokinase/hirudin heterodimers are claimed.